TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

Official record

Identifier

NCT07836309

Recruiting locations

country

China

Interventions studied

Not provided in the official record

Lead sponsor

Zhongda Hospital

Target enrolment

596 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Sep 23, 2026

Last updated on the registry

Sep 23, 2026

Age

16 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or patients who meet the clinical diagnostic criteria for primary liver cancer;
2. Age ≥18 years at the time of HCC diagnosis;
3. Barcelona Clinic Liver Cancer (BCLC) stage C;
4. No prior systemic therapy for HCC (including chemotherapy, molecular targeted therapy, or immunotherapy);
5. Received treatment with tislelizumab and lenvatinib, with the interval between the first administration of the two drugs ≤1 week;
6. In the experimental group, TACE was performed within 3 months before or after treatment with tislelizumab and lenvatinib;
7. After TACE, patients received at least one cycle of combination therapy with tislelizumab and lenvatinib, including cTACE and DEB-TACE;
8. Child-Pugh class A5 to B7;
9. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
10. At least one measurable intrahepatic lesion according to RECIST 1.1 criteria.

Exclusion Criteria:

1. Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma histological types;
2. Complete obstruction of the main portal vein with insufficient collateral compensation;
3. Uncontrollable ascites or hepatic encephalopathy;
4. Incomplete clinical data or missing essential information;
5. Presence of other primary malignant tumors in addition to the diagnosis of liver cancer;
6. Participation in other interventional studies prior to treatment;
7. Other conditions deemed unsuitable for inclusion by the investigators.

Indexed under

Liver Cancer